IMV Inc IMVIF

RE:Hurdle rate bladder and MSS High are super good

[alphaseeking001]

Anyone have access to the Wells Fargo note?  If so, could they post it up here?

Thanks

quote=Biotech010]

Wells Fargo analyst Nick Abbott put a $14 PT on the stock. You want to know why....????

The basket trial results from the KEYTRUDA combination data in MSS-high solid tumors and  bladder cancer are impressive. The so called hurdle rate... when to go / stop a trial... wasn't published in the press release. But this info was in the Wells Fargo report.

And the results were super good and way beyond what KEYTRUDA achieved in monotherapy. WIth this data coming up in Q4 2021... we should really see upward momentum for the stock.

Andrew en Jeremy are doing great work communicating and telling the IMV story.

 

[/quote]